Covidien Beats Estimates (COV)

4-27-12-Covidien (NYSE:COV) reported fiscal Q2 EPS of $1.05, topping estimates by $0.02.Revenues in the quarter rose 5.2% year-over-year to $2.95 billion, inline with estimates.Covidien PLC is a global healthcare products company. The Company develops, manufactures and distributes a diverse range of medical devices and supplies, diagnostics imaging agents, pharmaceuticals and other healthcare products for use in clinical and home settings.SmarTrend is bullish on shares of Covidien and our subscribers were alerted to buy on January 03, 2012 at $46.02. The stock has risen 19.6% since the alert was issued.